AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00098839
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00393718
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glibenclamide placebo. Given orally once or twice daily.
Trial: NCT01030614
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
Trial: NCT00098839
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/m2/day PO divided BID or TID
Trial: NCT00098839
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT
Trial: NCT00098839
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00098839
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02285530
Drug: TPF induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle.
Trial: NCT01938534
Drug: Helicobacter pylori eradication
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00531193
Drug: BIIB014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of BIIB014, given once daily for 8 to 12 consecutive days, at various doses as specified in protocol
Trial: NCT01174030
Drug: CD07805/47 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD07805/47 Gel 0.5% QD
Trial: NCT01174030
Drug: Vehicle Gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Gel QD
Trial: NCT01174030
Drug: CD07805/47 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD07805/47 Gel 0.18% QD
Trial: NCT01174030
Drug: CD07805/47 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD07805/47 Gel 0.18% BID
Trial: NCT01174030
Drug: Vehicle Gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Gel BID
Trial: NCT02624102
Drug: Antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with MDD, in use of antidepressants (fluoxetine, citalopram, escitalopram, bupropion, etc.) without psychotherapy.
Trial: NCT03100825
Drug: QVM149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate)
Trial: NCT06129812
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.
Trial: NCT01197469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00559962
Drug: AEGR-733
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules each evening for each 4-week period
Trial: NCT00559962
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules each evening for each 4-week period
Trial: NCT03410979
Drug: GLPG2737 single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG2737 oral suspension, single ascending doses
Trial: NCT03410979
Drug: Placebo single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral suspension.
Trial: NCT03410979
Drug: GLPG2737 multiple dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.
Trial: NCT03410979
Drug: GLPG2737 multiple dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral suspension, daily for 14 days
Trial: NCT02059148
Drug: LY2835219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00262990
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00756951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00756951
Drug: SCV-07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mg/kg
Trial: NCT00756951
Drug: SCV-07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.10 mg/kg
Trial: NCT00000480
Drug: anti-arrhythmia agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02231268
Drug: Gladem
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01994993
Drug: ampicillin and metronidazole and gentamicin
RxNorm normalized name: metronidazole and diloxanide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of ampicillin and metronidazole and gentamicin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
Trial: NCT01994993
Drug: ampicillin and gentamicin and clindamycin
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of ampicillin and gentamicin and clindamycin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
Trial: NCT01994993
Drug: gentamicin and Piperacillin- tazobactam
RxNorm normalized name: piperacillin / tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of gentamicin and Piperacillin- tazobactam for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
Trial: NCT01994993
Drug: metronidazole, clindamycin, or piperacillin-tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of metronidazole, clindamycin, or piperacillin-tazobactam with scheduled CSF procedures per standard of care. Study drug will be given for for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
Trial: NCT04680949
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care and placebo. Placebo is injected subcutaneously once daily for 10 days
Trial: NCT02412059
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04052776
Drug: Buspirone + Levodopa-Carbidopa
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg + 400mg/100mg
Trial: NCT04052776
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active metabolite
Trial: NCT00513396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar appearing and similarly packaged placebo tablets in addition to the standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
Trial: NCT00969072
Drug: GI198745 0.05mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GI198745 (drug) - benign prostatic hyperplasia
Trial: NCT00969072
Drug: GI198745 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GI198745 (drug) - benign prostatic hyperplasia
Trial: NCT00969072
Drug: GI198745 2.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GI198745 (drug) - benign prostatic hyperplasia
Trial: NCT01621867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)
Trial: NCT00003196
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo cytoreductive chemotherapy
Trial: NCT02558348
Drug: AL3818
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04538625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets
Trial: NCT04023682
Drug: Provodine Hand Sanitizer
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention with Provodine
Trial: NCT02386943
Drug: Blank control
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication is taken.
Trial: NCT04143451
Drug: Aldara 5% Topical Cream
RxNorm normalized name: Aldara 5% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imiquimod cream
Trial: NCT04143451
Drug: Aqueous cream BP
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive aqueous cream
Trial: NCT00940303
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg/m2 iv infusion, day 1 every 2 weeks
Trial: NCT02562313
Drug: Humalog®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humalog® bolus infusion followed by test meal intake
Trial: NCT00544596
Drug: R-(-)-gossypol acetic acid
RxNorm normalized name: citronellol acetate, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01493271
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to RO5093151
Trial: NCT01493271
Drug: RO5093151
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral doses twice daily for up to 28 days
Trial: NCT00099983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01107782
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg tid
Trial: NCT02963701
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fixed dose combination
Trial: NCT02886559
Drug: Chidamide plus DCAG regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chidamide, decitabine, aclarubicin, cytarabine and G-CSF
Trial: NCT03704181
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo twice day for one year
Trial: NCT01181258
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg administered intravenously (IV) for 2 hours on day -5 after Fludarabine.
Trial: NCT00696969
Drug: Ambisome and Paromomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambisome 5 mg/kg single dose + Paromomycin Sulphate 15mg/kg/day for 10 days
Trial: NCT00696969
Drug: Miltefosine and Paromomycin
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miltefosine (standard dose) and Paromomycin Sulphate 15mg/kg/day for 10 days
Trial: NCT00752726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive
Trial: NCT00547521
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants who were currently receiving methotrexate at a stable dose ≥ 10 mg for at least 4 weeks
Trial: NCT03875664
Drug: Placebo - injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable normal saline solution
Trial: NCT00629473
Drug: NPI-0052 on Days 1, 8, 15 every 28 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPI-0052 dose ranging from 0.1 to 0.9 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 8, and 15 of 4-week cycles
Trial: NCT00629473
Drug: NPI-0052 on Days 1, 4, 8, 11 every 21 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPI-0052 dose ranging from 0.075 to 0.6 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 4, 8, and 11 of 3-week cycles
Trial: NCT00670228
Drug: Standard Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin therapy titrated to blood sugar control
Trial: NCT03042260
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
Trial: NCT00528996
Drug: BEA 2180 BR
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution
Trial: NCT00528996
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution
Trial: NCT02379468
Drug: Pedyphar Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02913768
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01756118
Drug: BEZ235
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A minimum of 3 dose levels
Trial: NCT01099436
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01099436
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01099436
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02081599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03404622
Drug: IUCD
RxNorm normalized name: Intrauterine contraceptive device (IUCD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IUCD will be inserted in 100 women post placental removal and will be inserted in anther 100 women after six weeks post cesarean delivery
Trial: NCT01469065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of PF-04991532 Matching Placebo; given twice a day (BID) for 14 days
Trial: NCT00700583
Drug: combination therapy of terazosin and hydrochlorothiazide
RxNorm normalized name: combinations of levothyroxine and liothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of hydrochlorothiazide eight hours before bedtime and 4 mg of terazosin at bedtime for 4 weeks
Trial: NCT03917134
Drug: cephalosporin + Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of cephalosporin in doses of 2 grams administered intravenously before surgery and vaginal ovules of placebo twice a day for 5 days after performing laparoscopic hysterectomy
Trial: NCT00006094
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04673916
Drug: Healing evaluation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatments were topically applied for 5 days
Trial: NCT01441427
Drug: recombinant human G-CSF, and rhEPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF 4.5 microgram /kg/day enteral EPO 88 mIU/kg/day enteral
Trial: NCT01441427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: distilled water :1 ml distilled water administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
Trial: NCT03244228
Drug: HTL0016878
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT03244228
Drug: Placebo - Concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00647192
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg per day
Trial: NCT00647192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg per day
Trial: NCT01566578
Drug: Human recombinant epidermal growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical
Trial: NCT02506660
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02506660
Drug: Perineural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline in nerve block
Trial: NCT00773890
Drug: TRF-1101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily treatment with 300 mg orally for 12 weeks
Trial: NCT00773890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily treatment with TRF-1101 vehicle for 12 weeks
Trial: NCT01331928
Drug: Capecitabine (Xeloda, Roche), Oxaliplatin (Sanofi-Aventis), Docetaxel (Sanofi-Aventis)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capecitabine orally 1000 mg/m2 twice daily, day1 to day 10, every 2 weeks plus oxaliplatin 85mg/m2 (2hrs IV infusion)on day1, every 2 weeks for 6 cycles, then shift to docetaxel 30 mg/m2(over 30-minute intravenous infusion) on day 1 and day 8 plus oral capecitabine 825 mg/m2 twice daily on day 1 to 14, every 3 weeks for 4 cycles.
Trial: NCT01659099
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in ACBVP : 75 mg/m² on D1 in CHOP : 50 mg/m² on D1
Trial: NCT01659099
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: in ACBVP : 1200 mg/m² on D1 in CHOP : 750 mg/m² on D1
Trial: NCT02066415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once a month subcutaneously by authorized investigational site study staff.
Trial: NCT02652416
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00789633
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo given orally twice daily
Trial: NCT03446417
Drug: ZN-e4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose, tablet, daily dosing
Trial: NCT04185415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical Form: Solution for infusion~* Concentration: 0.9% w/v sodium chloride aqueous solution~* Route of Administration: Intravenous
Trial: NCT02220751
Drug: non-surgical periodontal therapy + systemic doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.~Non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before the first scaling and root planning session. Patients of the PD group had no access to information about antibiotics administration to patients of the PD+DM group.
Trial: NCT02792998
Drug: IW-1701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IW-1701 Tablet
Trial: NCT02792998
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo Tablet
Trial: NCT01369186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. bolus injection
Trial: NCT00821912
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1650 mg/m2 /day orally b.i.d., day 1-14 every 3 weeks.
Trial: NCT01793259
Drug: methotrexate prefilled pen
RxNorm normalized name: methotrexate Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01793259
Drug: methotrexate prefilled syringe
RxNorm normalized name: methotrexate Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04025177
Drug: Indomethacin Injection
RxNorm normalized name: indomethacin Injection
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose of indomethacin will be 0.1 mg/kg/dose, based on birth weight, intravenously every 24 hours for a total of 3 doses. Doses 2 and 3 may be administered between 23.5 and 24.5 hours after the previous dose. Doses will be rounded to two significant figures.
Trial: NCT01302054
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for fesoterodine 4 and 8 mg for a total of 12 weeks.
Trial: NCT04569994
Drug: NNC0363-0845
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose administered s.c. (subcutaneously, under the skin)
Trial: NCT02063997
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once daily for 12 weeks
Trial: NCT04569994
Drug: Placebo (NNC0363-0845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose administered s.c.
Trial: NCT04498351
Drug: Control Test
RxNorm normalized name: CHEK-STIX URINALYSIS CONTROL TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spermatic cord block by18ml levobupivacaine 0.5% plus 2 ml normal saline in total volume of 20 ml.~The procedure is repeated on the contralateral side.
Trial: NCT04630522
Drug: Drug: JMT103- 120 mg SC Q4W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 4-week cycle.
Trial: NCT04630522
Drug: Drug: JMT103- 120 mg SC Q8W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 8-week cycle.
Trial: NCT04630522
Drug: Drug: JMT103- 180 mg SC Q8W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JMT103 is administered subcutaneously at a dose of 180 mg on day 1 of each 8-week cycle.
Trial: NCT01873690
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Dextrose in water